ACCESS Newswire

MicroVision, Inc.

27.4.2022 22:21:08 CEST | ACCESS Newswire | Press release

Share
MicroVision Announces First Quarter 2022 Results

REDMOND, WA / ACCESSWIRE / April 27, 2022 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced its first quarter 2022 results.

"We made significant progress in the first quarter of 2022. We track tested our integrated Long Range Lidar sensor and perception software, demonstrating promising ground-truth data of our high-fidelity/low-latency solution at speeds of over 60 mph," said Sumit Sharma, MicroVision's Chief Executive Officer. "We continue to receive positive feedback and interest from automotive OEMs and Tier 1 suppliers for our best-in-class product with cost advantages."

"We began our testing in the U.S. and expect to conduct several more rounds of tests of our high-speed Highway Pilot system both in the U.S. and Germany during the second quarter as we work to deliver on our 2022 objectives," continued Sharma.

Key Financial Highlights for Q1 2022

  • Revenue for the first quarter of 2022 was $0.4 million, compared to $0.5 million for the first quarter of 2021.
  • Net loss for the first quarter of 2022 was $13.2 million, or $0.08 per share, which includes $3.7 million of non-cash, share-based compensation expense, compared to a net loss of $6.2 million, or $0.04 per share, which includes $1.6 million of non-cash, share-based compensation expense, for the first quarter of 2021.
  • Adjusted EBITDA for the first quarter of 2022 was negative $9.0 million, compared to negative $4.3 million in the first quarter of 2021.
  • Cash used in operations for the first quarter of 2022 was $10.9 million, compared to cash used in operations for the first quarter in 2021 of $4.5 million.
  • The Company ended the first quarter of 2022 with $103.3 million in cash and cash equivalents including investment securities, compared to $115.4 million at the end of December 31, 2021.

Conference Call and Webcast: Q1 2022 Results

MicroVision will host a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session at 2:00 PM PT/5:00 PM ET on Wednesday, April 27, 2022 to discuss the financial results and provide a business update. Analysts and investors may pose questions for management during the live webcast on April 27, 2022.

The live webcast and slide presentation can be accessed on the Company's Investor Relations website under the Events tab at https://ir.microvision.com/events. The webcast will be archived on the website for future viewing.

About MicroVision

MicroVision is a pioneering company in MEMS based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms and machine learning software into its proprietary technology to address existing and emerging markets. The Company's integrated approach uses its proprietary technology today to develop automotive lidar sensors and provide solutions for advanced driver-assisted systems (ADAS), leveraging its experience building augmented reality micro-display engines, interactive display modules and consumer lidar modules.

For more information, visit the Company's website at www.microvision.com, on Facebook at www.facebook.com/microvisionincor follow MicroVision on Twitter at @MicroVision.

MicroVision is a trademark of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.

Non-GAAP information

To supplement MicroVision's condensed financial statements presented in accordance with GAAP, the Company presents investors with the non-GAAP financial measure "adjusted EBITDA." Adjusted EBITDA consists of GAAP net income (loss) excluding the impact of the following: interest income and interest expense; income tax expense; depreciation and amortization; and share-based compensation.

MicroVision believes that the presentation of adjusted EBITDA provides important supplemental information to management and investors regarding financial and business trends, provides consistency and comparability with MicroVision's past financial reports, and facilitates comparisons with other companies in the Company's industry, many of which use similar non-GAAP financial measures to supplement their GAAP results. Internally, management uses this non-GAAP measure when evaluating operating performance because the exclusion of the items described above provides an additional useful measure of the Company's operating results and facilitates comparisons of the Company's core operating performance against prior periods and its business objectives. Externally, the Company believes that adjusted EBITDA is useful to investors in their assessment of MicroVision's operating performance and the valuation of the Company.

Adjusted EBITDA is not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of MicroVision's business as determined in accordance with GAAP. The Company expects to continue to incur expenses similar to the non-GAAP adjustments described above, and exclusion of these items from its non-GAAP financial measure should not be construed as an inference that these costs are unusual or infrequent. The Company compensates for limitations of the measure by prominently disclosing GAAP net income (loss), which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation from GAAP net income (loss) to adjusted EBITDA.

MicroVision has included a reconciliation of GAAP net income (loss) to adjusted EBITDA for the relevant periods.

Forward-Looking Statements

Certain statements contained in this release, including the Company's plans regarding product demonstration and product capabilities are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in such forward-looking statements include the risk its ability to operate with limited cash or to raise additional capital when needed; market acceptance of its technologies and products or for products incorporating its technologies; the failure of its commercial partners to perform as expected under its agreements, including from the impact of COVID-19 (coronavirus); its financial and technical resources relative to those of its competitors; its ability to keep up with rapid technological change; government regulation of its technologies; its ability to enforce its intellectual property rights and protect its proprietary technologies; the ability to obtain customers and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market its products; potential product liability claims; its ability to maintain its listing on The Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect the Company. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect the Company to a greater extent than indicated. Except as expressly required by federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

MicroVision, Inc.
Balance Sheet
(In thousands)
(Unaudited)

March 31, December 31,
2022 2021
Assets
Current Assets
Cash and cash equivalents
$55,611 $82,647
Investment securities, available-for-sale
47,651 32,720
Inventory
1,815 1,780
Other current assets
1,865 2,283
Total current assets
106,942 119,430
Property and equipment, net
3,248 3,026
Operating lease right-of-use asset
5,368 5,577
Restricted cash
1,092 1,092
Intangible assets, net
105 115
Other assets
1,014 985
Total assets
$117,769 $130,225
Liabilities and Shareholders' Equity
Current Liabilities
Accounts payable
$1,919 $3,584
Accrued liabilities
1,288 1,170
Contract liabilities
4,915 5,265
Other current liabilities
474 1,181
Current portion of long-term debt
98 392
Current portion of operating lease liability
686 849
Current portion of finance lease obligations
24 21
Total current liabilities
9,404 12,462
Operating lease liability, net of current portion
4,882 4,983
Finance lease obligations, net of current portion
15 26
Total liabilities
14,301 17,471
Commitments and contingencies
Shareholders' Equity
Common stock at par value
165 164
Additional paid-in capital
746,028 742,042
Accumulated other comprehensive loss
(124) (19)
Accumulated deficit
(642,601) (629,433)
Total shareholders' equity
103,468 112,754
Total liabilities and shareholders' equity
$117,769 $130,225

MicroVision, Inc.
Statement of Operations
(In thousands, except earnings per share data)
(Unaudited)

Three months ended March 31,
2022 2021
Product revenue
$- $-
License and royalty revenue
350 479
Total revenue
350 479
Cost of product revenue
4 (5)
Total cost of revenue
4 (5)
Gross margin
346 484
Research and development expense
7,593 4,462
Sales, marketing, general and administrative expense
5,877 2,247
Total operating expenses
13,470 6,709
Loss from operations
(13,124) (6,225)
Other expense, net
(44) (6)
Net loss
$(13,168) $(6,231)
Net loss per share - basic and diluted
$(0.08) $(0.04)
Weighted-average shares outstanding - basic and diluted
164,563 155,454

MicroVision, Inc.
Reconciliation of GAAP Net Loss to Non-GAAP Measure
(In thousands, except earnings per share data)
(Unaudited)


Three months ended March 31,

2022 2021






GAAP net loss
$(13,168) $(6,231)
Add Interest (net)
(31) 5
Add Income taxes
- -
Add Depreciation & amorization
483 299
Add Share-based compensation expense
3,734 1,638
Adjusted EBITDA
$(8,982) $(4,289)

Investor Relations Contact

Jeff Christensen and Matt Kreps
Darrow Associates Investor Relations
MVIS@darrowir.com

SOURCE: MicroVision, Inc.



View source version on accesswire.com:
https://www.accesswire.com/699143/MicroVision-Announces-First-Quarter-2022-Results

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Flow Technology partners with BW Forsyth Partners to Meet Growing Demand for Biopharmaceutical Manufacturing7.9.2026 10:00:00 CEST | Press release

Investment supports Flow Technology's ability to help pharmaceutical and biotechnology manufacturers expand production and navigate increasingly complex manufacturing requirements CHARLEVILLE, IRELAND / ACCESS Newswire / September 7, 2026 / Flow Technology, a provider of engineered process systems and skid integration solutions serving the global life sciences industry, announced a partnership with BW Forsyth Partners that will support the company's continued expansion in the United States and Europe, and enhance its ability to serve the evolving needs of global pharmaceutical and biotechnology manufacturers. The partnership comes as pharmaceutical and biotechnology companies invest heavily in production capacity, advanced manufacturing technologies and domestic supply chains. Flow Technology's expertise in downstream purification, filtration and chromatography systems positions the company to support the increasingly sophisticated process infrastructure required to manufacture next-ge

LiberNovo Showcases Dynamic Ergonomic Seating at IFA 2026 and Supports Special Olympics New York4.9.2026 18:30:00 CEST | Press release

Maxis Series Brings More Space, Support and Choice to Big & Tall Users BERLIN, DE / ACCESS Newswire / September 4, 2026 / LiberNovo is exhibiting at IFA 2026 from September 4 to 8 at Messe Berlin, presenting its dynamic ergonomic seating range at Hall 7, Stand 7.2a-105. The Maxis Series leads the stand, alongside the LiberNovo Omni Pro and Omni SE. LiberNovo Omni Pro has also earned nominations in two IFA Innovation Awards categories: Best in Design and Best in Tech for Good & Accessibility. IFA is a leading event for consumer technology and home appliances, connecting brands, retailers, buyers and media. Its 2026 theme, "The future is now," highlights technology reshaping everyday life. As hybrid work, gaming and content creation extend sitting time, LiberNovo presents seating as an active support system rather than a static object. Maxis Series: Built for Bigger Builds Maxis was designed for taller, broader and heavier users rather than scaled up from a standard chair. Its 52 cm (20.

Suntex Enterprises Launches Ambitious $1 Billion+ North American Real Estate Development Initiative4.9.2026 13:30:00 CEST | Press release

Two major Alberta projects are projected to generate approximately $575 million in revenue as Suntex expands its integrated development, construction, and ownership platform throughout Canada and the United States. AUSTIN, TX / ACCESS Newswire / September 4, 2026 / Suntex Enterprises, Inc. (OTCID:SNTX) ("Suntex" or the "Company"), a dynamic operating and holding company dedicated to real estate development, construction, infrastructure, and land, proudly announces the signing of a Letter of Intent ("LOI") that advances a transformative multiyear real estate development partnership across North America. The LOI builds upon the Canadian development relationship unveiled by Suntex in July 2026 and lays the groundwork for a robust initial portfolio of large-scale development opportunities designed to drive substantial growth across the Company's expanding North American platform. The portfolio is anchored by Royal Links in Leduc, Alberta, and Meridian in Alberta, representing $575 million

Formerra Receives 2026 Eaton Supplier Excellence Award3.9.2026 16:45:00 CEST | Press release

Recognition places Formerra among several dozen honorees from a supplier network of more than 30,000. ROMEOVILLE, IL / ACCESS Newswire / September 3, 2026 / Formerra, a leader in performance materials distribution, was recognized for its partnership at Eaton's 2026 Global Supplier Conference & Excellence Awards, held Thursday, August 27 in Beachwood, Ohio. Formerra was one of only 30 suppliers recognized with Eaton's Supplier Excellence Award from among the company's global network of more than 30,000 supplier partners. Eaton grants the Supplier Excellence Award to suppliers that exceed expectations through exceptional performance, innovation, and contributions to growth. Formerra serves as Eaton's preferred plastics distribution partner, a role built through disciplined execution and engagement across Eaton's corporate organization and manufacturing sites. While the partnership began over 15 years ago in North America, it now extends into Asia, Europe, and the Middle East, where Forme

DistillerSR Joins European MedTech Consortium to Digitalize Medical Device and IVD Conformity Assessments3.9.2026 16:00:00 CEST | Press release

€4 million European-funded DIGICAP project brings together 19 organizations to replace document-based conformity assessments with machine-readable data. DistillerSR named one of five technology providers building the framework. OTTAWA, ON / ACCESS Newswire / September 3, 2026 / DistillerSR, the market leader in AI-enabled literature review automation and evidence management, today announced its participation in DIGICAP (DIGItalisation of the Conformity Assessment Process), a €4 million European initiative uniting 19 organizations across 12 EU countries to digitalize how medical devices and in vitro diagnostics are certified for the European market. The project is funded under Horizon Europe, the world's largest multinational research and innovation program, with a budget of €95.5 billion for the 2021-2027 period. DistillerSR is one of five regulatory technology providers selected to support the project, alongside Veeva, MEDDEVO, AUREVIA and Hardian Health. The company will work in the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye